Abstract
ObjectiveThe objective of this study was to investigate the utility of vasorin, a newly discovered transmembrane protein, as a novel biomarker in the early detection of colon cancer.MethodsA total of 80 patients aged 55-70 years, diagnosed with colon cancer and followed up in our clinics, and 50 healthy volunteer blood donors were included in the study. Participants' demographics such as age, gender, and vasorin levels were recorded and compared between the patient and control groups. In addition, primary tumor status (pT) values N and T stages of the tumors were studied in the patient group. All patients included in the study were pathologically confirmed by colonoscopy plus biopsy and postoperative histopathologic examination.ResultsThe mean age was found as 64.59±3.70 (min-max: 55-70) years old in the patient group and 63.56±3.07 (min-max: 57-70) years. There was no statistically significant difference between both groups regarding demographics (p>0.05). Serum Vasorin levels were higher in patients with colon cancer than in the control group (p<0.001). Serum Vasorin levels were higher among patients with advanced disease and related to the clinical stage of the locally advanced tumor. ConclusionOur findings revealed that serum vasorin levels are upregulated in patients with colon cancer. Raised vasorin levels may be a non-invasive biomarker beneficial for early detection and prediction of colon cancer prognosis. In addition, vasorin levels further rose as the disease advanced to higher TNM (tumor (T), nodes (N), and metastases (M)) stages. Further comprehensive studies are needed to draw more evident conclusions and generalize our results.
Highlights
Colorectal cancer (CRC) is the third most frequent malignancy worldwide, with an estimated 1.93 million newly diagnosed CRC cases and 0.94 million CRC-related deaths in 2020 [1]
Serum Vasorin levels were higher in patients with colon cancer than in the control group (p
Serum Vasorin levels were higher among patients with advanced disease and related to the clinical stage of the locally advanced tumor
Summary
Colorectal cancer (CRC) is the third most frequent malignancy worldwide, with an estimated 1.93 million newly diagnosed CRC cases and 0.94 million CRC-related deaths in 2020 [1]. CRC is the second leading cause of cancer death globally due to unmet screening programs and therapeutic strategies and increasing incidence. A broad spectrum of causes play a role in the development of CRC, including modifiable factors such as obesity, smoking, alcohol abuse, diet, sedentary lifestyle and access to health care services, and nonmodifiable factors such as age, gender, family history, and genetics) [3]. It has been reported that at least half of CRC cases could be prevented by reducing modifiable factors, including those related to lifestyle [4]. The increasing incidence of CTC has been associated with the shifting lifestyle and diet towards westernization [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
